Biotech forum daily digest_ can biotech rebound in november_ revisiting redhill biopharma – redhill biopharma ltd. (nasdaq_rdhl) _ seeking alpha

Biotech investors have to be happy that October is officially in the books. V lab electricity It was a dismal month for this part of the market. Us electricity hertz The main biotech indices fell over 10% on the month. Gas in chest Myriad small-cap names in the industry were down 20% to 30% in October for no other reason than a shift in sentiment on this part of the sector.

However, November should bring brighter skies for investors in this high-beta area of equities. Electricity word search printable Based on the latest polls, the Republicans are a virtual lock to retain the House of Representatives. Electricity merit badge worksheet answers Based on the latest RealClearPolitics average, they also look like around a 50/50 proposition to keep the Senate as well.

Any election outcome that results in a split government should be good for both the biotech & pharma sectors as it removes the possibility of any major legislative changes that could negatively impact these industries. Electricity billy elliot chords I believe a year-end rally is a likely outcome of the November 8th vote in these areas of the market given how oversold they have recently become.

Note: To get these Biotech Forum Daily Digests as soon as they are published, just click on my profile, hit the big, orange “Follow” button, and choose the real-time alerts option.

Valeant Pharmaceuticals (NYSE: VRX) is getting a huge bounce today as it is “shopping” its 2015 purchase of Salix Pharmaceuticals (NASDAQ: SLXP) for some $10 billion. Electricity towers in japan That is a far cry from the almost $15 billion it bought the firm for last year. Gas in back and stomach However, investors are applauding any efforts that could substantially reduce the one-time drug giant’s onerous ~$30 billion debt load.

One small cap that could benefit if Valeant is successful in finding a partner for these gastrointestinal assets would be Progenics Pharmaceuticals (NASDAQ: PGNX), which I wrote about earlier today.

Biotech stalwart Gilead Sciences (NASDAQ: GILD) reported third quarter results after the bell on Tuesday. Electricity prices per kwh 2013 The company delivered $2.75 a share of EPS, a dime less than expected. Electricity games Revenues fell nearly 10% year over year but came in around $50 million above expectations.

Given the bottom-line “miss”, the stock held up well in trading and is down less than 2 percent at mid-day. Grade 9 electricity unit test answers The company is seeing very good growth out of its non-HCV portfolio. Gaston yla agrupacion santa fe Maybe the bottom is finally in on this beaten down name that seems undervalued using a “sum-of-the-parts” valuation. Tgas advisors company profile We will do a deeper dive on this possibility later in the week.

It appears that the chances of antibiotic “solithromycin” from Cempra (NASDAQ: CEMP) being approved at its PDUFA date in late December have gone from good to slim & none over the past week. Electricity icons free Late last month, concerns around the facility in India that was slated to make a component of the compound came to light. Power outage houston today That could have produced a delay, but not caused the outright rejection of the drug.

Today, more serious issues arose as data showed a ” genuine liver injury signal.” This may not mean the end of solithromycin, but will mean Cempra will have to do larger studies, which will substantially move back any projected launch date for this antibiotic. Electricity voltage in germany The stock is down some 50% in early trading. Electricity worksheets ks1 I “whiffed” on this one as did analysts from Needham, Jefferies, Cowen & Co., Morgan Stanley, etc. Electricity and circuits It just shows there are no sure things in the developmental space and shows the need to keep stakes small in this niche of biotech/biopharma and one’s overall portfolio very diversified in this very high-beta part of the market.

Going in the other direction in trading today, is another small biopharma I have done several positive profiles on, Eagle Pharmaceuticals (NASDAQ: EGRX). Electricity vs magnetism venn diagram The stock is up some 20% in early trading as the company announced today that the Centers for Medicare & Medicaid Services has established a unique, product-specific billing code, or J-code (J9034), for BENDEKA® (bendamustine hydrochloride) Injection. Electricity 2pm lyrics The J-code will become effective on January 1, 2017. Gas law questions and answers This should help boost sales of this compound, which is marketed and distributed by partner Teva Pharmaceuticals (NASDAQ: TEVA).

Morgan Stanley was the first to jump on the Valeant bandwagon after news of the potential sale of Salix Pharmaceuticals came to light. F gas regulations After four Hold or Sell ratings in October, Morgan issues the first Buy rating on Valeant since early September and puts a $42 price target on the shares as well.

Flexion Therapeutics (NASDAQ: FLXN) saw some positive analyst commentary Tuesday. Z gas cd juarez telefono Cantor Fitzgerald reissued its Buy rating and $40 price target and Wells Fargo reiterated its Outperform rating and $30 price target on Flexion yesterday.

The company posted positive mid-stage trial results for its lead drug candidate in type 2 diabetics with osteoarthritis ((NYSE: OA)) of the knee. Astrid y gaston lima menu prices Flexion is a recent addition to the Insiders Forum portfolio not only because of its attractive risk/reward profile but also because of recent insider buying in the name.

Ionis Pharmaceuticals (NASDAQ: IONS) received its first analyst mention in over three weeks today as Piper Jaffray reissued its Buy rating. Gas under a dollar Ionis and and its partner Bayer ( OTCPK:BAYRY) just reported positive data from a Phase 2 study of IONS-FXI, an anti-clotting antisense therapeutic, which targets Factor 11 to prevent thrombosis which should put Ionis in line for a $55 million milestone payment in addition to advancing the drug from a developmental perspective.

Note: New analyst ratings are a great place to begin your due diligence, but nothing substitutes for deeper individual research in this very volatile sector of the market. Find a gas station near me Many of the small-cap names highlighted in the “Analyst Insight” will eventually appear in the “Spotlight” section, where we do deeper dives on this type of promising but speculative small-cap concern.

In today’s Spotlight section we are revisiting the investment case for Redhill Biopharma (NASDAQ: RDHL), which is in the news this week as it pulled a secondary offering. Electricity number The company also have several potential catalysts within its pipeline over the next nine months.

Redhill Biopharma is a late-stage Israeli concern focused on orally-administered drugs for the treatment of inflammatory and gastrointestinal diseases, including cancer. Electricity quiz 4th grade The company has a market capitalization of approximately $150 million and trades near $12 a share, right in the middle of its 52 week range.

This is being targeted at both Crohn’s disease & Multiple Sclerosis. V gas llc A Phase 3 safety analysis is due out on the former by the end of the year. Gas finder near me An interim efficacy analysis should post as well in the second quarter of 2017. Rahal e gas card A Phase 2a study should hit around Multiple Sclerosis by the end of the year as well.

The company has a quarterly burn rate that is averaging $5 million to $6 million a quarter and has just over $45 million in cash & marketable securities on hand as of the end of the second quarter so is well-funded for the time being.

The median analyst price target on RDHL is north of $30 a share currently. Gas dryer vs electric dryer calculator Since early October, Roth Capital, H.C. Electricity production in usa Wainwright and FBR Capital have all reiterated Buy ratings with price targets ranging from $26 to $36 a share.

FBR was the last analyst firm to rate Redhill on October 11th and has the most optimistic price target on the stock. Gas variables pogil answers Its analyst noted the reason for his enthusiasm and $36 price target on Redhill “We look for progress in Redhill Biopharma’s clinical-stage programs to continue being translated into stock appreciation. Gas x coupon 2014 We think significant milestones remain such as an independent Data Safety and Monitoring Board (DSMB) safety assessment of RHB-104 in Phase 3 testing in Crohn’s disease (the MAP US study) expected by year-end 2016 and an efficacy review for stopping MAP US early due to overwhelming efficacy expected in 2Q17, which could be positive catalysts for the stock in the next three to six months. Gas zyklon b We think the potential of these catalysts to result in stock appreciation, as well as others such as continued success expanding the worldwide market potential of Redhill’s first commercialized product, Rizaport, and progress with Yeliva in mid-stage testing in multiple oncology indications, remain under-recognized.” Which heavily notes some of the milestones I provided a synopsis of above.

Although the sentiment on the small biotech & biopharma space is currently dismal, Redhill has many of the traits I think make it have a favorable risk/reward profile at the present time. Gas tax in washington state It has multiple shots on goal, is targeting addressable markets, has upcoming milestones, has funding in place and has strong analyst support. Electricity youtube I remain optimistic on its prospects and think the company should garner more notice in 2017 given the trajectory/milestones of its pipeline.